Terns Pharma Q3 net loss $21.9M; cash $372.8M; TERN-701 data Dec 2024, TERN-601 Phase 2 start 2Q25

Terns Pharmaceuticals, Inc.

2024-Q3 EPS reported -$0.89

Net loss of $21.9M ($0.28/share) vs $29.8M loss ($0.42) in Q3 2023; R&D $15.2M, G&A $9.8M.
Cash, equivalents and marketable securities $372.8M (incl. $172.7M equity raise in Sep) providing runway into 2028.
Interim Phase 1 CARDINAL data for TERN-701 (allosteric BCR-ABL TKI in CML) expected early December 2024.
Phase 2 trial for TERN-601 (oral GLP-1R agonist for obesity) to start early 2Q25; initial 12-week data in 2H25.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.